glp-1 psychiatry GLP-1s may improve some mental health outcomes in addition to lowering body weight Insights into a possible role

Changes in menstrual cycles while on semaglutide could be multifactorial

Prevention candidates: Given the observational data suggesting reduced autoimmune disease risk in GLP-1 users, some practitioners are considering microdosing for patients with strong family histories or early biomarker evidence of autoimmune activation before clinical disease manifests

As both diabetes diagnoses and the life expectancy of individuals with diabetes continue to rise, the total number of diabetic patients is expected to reach 629 million by 2045 [1], resulting in an increasing demand for anti-diabetes therapies

This leads to: Reduced Appetite: Encouraging lower calorie intake without the discomfort of hunger

Mead E, Atkinson G, Richter B, et al

This litigation is moving forward